Next Article in Journal
Histone Deacetylases and Their Inhibitors in Cancer Epigenetics
Previous Article in Journal
Rapid Induction and Maintenance of Remission in Refractory Ulcerative Colitis with Ustekinumab
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Diseases
Volume 7
Issue 4
10.3390/diseases7040056
diseases-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

HIV Capsid Inhibitors Beyond PF74

by
Carole McArthur
1,2,3,*,
Fabio Gallazzi
4,5,
Thomas P. Quinn
6 and
Kamal Singh
4,7,8,*
1
Department of Oral and Craniofacial Sciences, School of Dentistry, University of Missouri, Kansas City, MO 64108, USA
2
Kansas City School of Medicine, University of Missouri, Kansas City, MO 64108, USA
3
Department of Pathology, Truman Medical Center, Kansas City, MO, 64108, USA
4
Bond Life Sciences Center, University of Missouri, Columbia, MO 65211, USA
5
Department of Chemistry, University of Missouri, Columbia, MO 65211, USA
6
Department of Biochemistry, University of Missouri, Columbia, MO 65211, USA
7
Department of Molecular Microbiology and Immunology, University of Missouri, Columbia, MO 65211, USA
8
Division of Clinical Microbiology, Department of Laboratory Medicine, Karolinska Institute, 14186 Stockholm, Sweden
*
Authors to whom correspondence should be addressed.
Diseases 2019, 7(4), 56; https://doi.org/10.3390/diseases7040056
Submission received: 20 September 2019 / Revised: 21 October 2019 / Accepted: 27 October 2019 / Published: 30 October 2019
(This article belongs to the Section Infectious Disease)
Browse Figures
Versions Notes

Abstract

:
Human immunodeficiency virus (HIV) capsid plays important roles at multiple stages of viral replication. At the initial stages, controlled uncoating (disassembly) of the capsid ensures efficient reverse transcription of the single-stranded RNA genome, into the double-stranded DNA. Whereas at later stages, a proper assembly of capsid ensures the formation of a mature infectious virus particle. Hence, the inhibition of capsid assembly and/or disassembly has been recognized as a potential therapeutic strategy, and several capsid inhibitors have been reported. Of these, PF-3450074 (PF74) has been extensively studied. Recently reported GS-CA inhibitors (GS-CA1 and GS-6207), have shown a strong potential and appear to contain a PF74 scaffold. The location of resistance mutations and the results of structural studies further suggest that GS-CA compounds and PF74 share the same binding pocket, which is located between capsid monomers. Additionally, phenylalanine derivatives containing the PF74 scaffold show slightly enhanced capsid inhibiting activity. A comparison of capsid structures in complex with host factors and PF74, reveals the presence of common chemical entities at topologically equivalent positions. Here we present the status of capsid inhibitors that contain PF74 scaffolds and propose that the PF74 scaffold may be used to develop strong and safe capsid inhibitors.

1. Introduction

Currently recommended antiretroviral therapies (cART) effectively suppress HIV and maintain HIV viral load below the detection levels (<50 copies/mL). As a result, HIV/AIDS is now a chronic and manageable disease [1,2,3,4,5,6]. However, HIV diversity, HIV persistence and the emergence of or the transfer of drug resistance mutations (DRMs) challenges the optimal outcome. Hence, new antiviral targets and agents that can inhibit HIV-1 replication through novel mechanisms are constantly sought. One such target is the HIV capsid, a structural protein that plays important roles at multiple stages of viral replication.
The capsid monomer (CA) is a 24 kDa α-helical protein with two distinct domains: an N-terminal domain (NTD) and a C-terminal domain (CTD) connected by a five residue flexible linker (Figure 1). During late stages of viral replication, the Gag polyprotein localizes at the plasma membrane and buds off as spherical, immature non-infectious virus. Auto-cleavage of the viral protease during maturation and the subsequent processing of the Gag polyprotein generates several structural proteins and small peptides, including capsid monomers (Figure 1a). These CA monomers then assemble into ~250 hexamers (Figure 1b) and 12 pentamers (Figure 1c) to form a mature fullerene-like core structure known as capsid core (hereafter referred to as capsid) (Figure 1d) [7,8].
At the early stages of HIV-1 infection, i.e., after infection and the fusion of the viral envelope with the host cell membrane, capsid is released into the cytosol where it undergoes controlled disassembly (uncoating). While the timing, mechanism, and extent of capsid uncoating is controversial [10,11,12,13,14,15,16,17,18], published reports suggest that capsid uncoating is associated with the initiation or continuation of the reverse transcription [14,19,20,21,22,23,24], and integration of viral DNA into the host chromosome [17,20,25,26,27,28]. Cosnefroy et al. [29] showed that HIV-1 capsid uncoating initiates after the first strand transfer of reverse transcription. Another report demonstrated that HIV-1 core undergoes morphological changes during reverse transcription [30]. These studies suggest that reverse transcription initiates within the virus particle and continues with capsid disassembly in the cytoplasm of the infected cell. The uncoating of capsid also involves the interaction of capsid with viral proteins (e.g., reverse transcriptase and integrase) [12,13], and host proteins including cyclophilin A [17], kinesin [31], dynein [31,32], microtubules [33], nucleoporins NUP358 and NUP153 [34], cleavage and polyadenylation specificity factor 6 (CPSF6) [35,36], transportin 3 (TNPO3) [34], and β-karyopherin Transportin-1 (TRN-1) [37]. The uncoating of capsid is influenced by certain mutations that change stability. Second, interactions between CA protomers alter replication events that may severely affect viral infectivity [21,38]. The role of capsid in the above-mentioned processes highlights capsid as an attractive antiviral target for the development of inhibitors [39,40,41].

2. PF74 and Capsid Inhibitors Containing the PF74-Scaffold

Several capsid-binding small molecules, which inhibit viral replication have been identified [41,42,43,44,45,46,47,48,49,50,51,52]. One of the most studied inhibitors is PF-3450074, also known as PF74 (Figure 2a) [25,53,54,55]. It inhibits infection, blocks reverse transcription [56] and prevents replication in vitro [3]. PF74 binds in a pocket between the NTD and CTD of monomers [45,57,58]. The structure of PF74 can be divided in to three components: a polyphenyl core (red, Figure 2a), a linker (blue, Figure 2a) and an indole substituent (violet, Figure 2a) [59]. In the following sections, we discuss compounds that contain PF74 scaffolds and have potential as future capsid inhibitors.
Recently reported two capsid inhibitors, GS-CA1 (Figure 2b) and GS-62072 (an analog of GS-CA1) (Figure 2c) display greater potency than currently approved antivirals in vitro [60,61]. GS-CA1 inhibits HIV-1 replication in T-lymphocytes and peripheral blood mononuclear cells (PBMCs) with EC50s of 240 pM and 140 pM, respectively) [60]. Alternatively, GS-6207 inhibits HIV-1 in MT-4 cells and PBMCs with EC50s of 100 pM and 50 pM, respectively [61]. Both compounds also have a potential as long acting inhibitors [60,62,63]. Analyses of the structures of GS-CA1 and GS-6207 show that both compounds contain a polyphenyl core and the linker region similar to that in PF74 (Figure 2a–c).
The structure of GS-CA1/CA complex has been solved, but it is not available in the public domains such as the Protein Data Bank [64]. However, molecular docking studies shows that both GS-CA1, GS-6207and PF74, share the same binding site [65] which is located between capsid NTD and CTD [57,60,66]. The docking results show the rings of PF74 superpose on the different rings of GS-CA1 (dotted circles 1, 2, and 3 in Figure 2d). More specifically, one of the two phenyl rings of PF74 is at a topologically equivalent position in the indazole ring of GS-CA1 (Figure 2d, circle 1), and the other phenyl ring of PF74 superposes on the difluorobenzene ring of GS-CA1 (Figure 2d, circle 2). The indole ring of PF74 superposes closely on the tetrahydrocyclopenta-pyrazole ring of GS-CA1 (Figure 2d, circle 3). In addition, the polar groups of the two molecules (PF74 and GS-CA1) superpose well [65].
In vitro resistance selection experiments have identified mutations L56I, M66I, Q67H, N74D and A105E under GS-CA1 pressure [67]. Mutations Q67H, N74D, K70N, Q67H/N74S, Q67H/T107N, L56I, Q67H/N74D, M66I and T107N are associated with GS-6207 resistance in vitro [68]. Several of these mutations are either associated with PF74 resistance or they are in the vicinity of PF74 binding pocket [45,55,56,58,69]. These data further support molecular docking studies and implicate that GS-CA1 binds at the PF74 binding pocket as predicted recently [65].
Together with common structural moieties in GS-CA1, GS-6207 and PF74, the GS-CA compounds have additional chemical groups that have extensive interactions with the NTD of adjacent capsid monomer. More specifically, methanesulfonyl moiety of GS-CA1 and GS-6207 is within interacting distance of I37, P38, S41, I135 and N139 [65]. It is possible that these interactions result in a better binding affinity of CA with GS-CA1 than PF74 [65], which results in the enhanced potency of GS-CA compounds.
In order to dissect the small molecule binding site between two capsid monomers of an hexamer, we employed the SiteMap program [70] of Schrödinger Suite (Schrödinger Inc., NY) in the crystal structure of the hexamer/PF74 complex (after removing PF74) (PDB file 5HGL [69]). Six hydrophobic pockets between two capsid monomers, as predicted by the SiteMap program, are shown as orange wire-mesh in Figure 3. Three of these hydrophobic pockets (marked 1, 2 and 3 in Figure 3) are present at the topologically equivalent positions of the three ring-structures of PF74/GS-CA compounds; regions 4, 5 and 6 are close to methanesulfonyl moieties of GS-CA compounds (Figure 3). This analysis suggests that methanesulfonyl moiety of GS-CA compounds may adopt a conformation that is rotated by ~180° from the one predicted recently [65]. This analysis also indicates that the methyl groups of methanesulfonyl moiety may have been strategically incorporated in GS-CA compounds to improve binding to the capsid. It is unclear if methanesulfonyl groups contribute to the low solubility of these compounds. In spite of low solubility [61] and violation of theoretical rules of drug-likeliness [61,71,72], GS-CA compounds have a strong potential to be developed as long-acting drugs.
The proposal that interactions of compounds with both capsid monomers involved in binding site formation may enhance potency of PF74-based molecules, was recently studied by synthesizing phenylalanine derivatives and testing their inhibitory activity [59]. One of these compounds had a selectivity index (SI) (CC50/EC50) of 13.33 compared to the SI of PF74 (SI = 11.85) [59]. These results suggest that the PF74 scaffold can be used to develop better capsid inhibitors.
Another reported capsid inhibitor BI-2 that contains a partial PF-74 polyphenyl core binds at the PF74 binding site [57]. A superposition of capsid bound to PF74 (PDB files 4XFZ and 5HGL) [9,69] and BI-2 (PDB file 4U0F) [57] demonstrates that two phenyl rings of BI-2 superposed well with the phenyl rings of PF74 (Figure 2b) [65]. BI-2 does not have a chemical moiety equivalent to the indole ring of PF74, which forms some contacts with CTD. It appears that a greater potency of PF74 compared to BI-2 is also the result of interactions of the indole ring with capsid.

3. Similarity among PF74, PF74-Based Compounds and Host Factors

CPSF6 and NUP153 are host factors that have been implicated in nuclear entry of HIV-1 through their interactions with capsid [66,73,74,75,76,77,78,79]. CPSF6 is a pre-mRNA splicing factor and member of the serine/arginine-rich (SR) protein family [80]. It is predominately a nuclear protein but localizes with capsid in the cytoplasm [25,81]. Depletion of CPSF6 marginally increases viral infection [73,81]. NUP153 is a nucleoprotein located at the nucleus side of the nuclear pore complex (NPC) [74]. NUP153 participates in HIV-1 translocation to nucleus through the nuclear pore [16,76]. The role of CPSF6 and NUP153 together with other host factors in HIV-1 infection have been reviewed by Yamashita and Engelman [81].
The crystal structures of capsid bound to the peptides from CPSF6 (313–327) and NUP153 (1407–1423) have been reported [57]. Structural comparison shows that both CPSF6 and NUP153 peptides bind at the PF74/BI-2 binding site [52,57]. Therefore, as expected both PF74 and BI-2 interfere with CPSF6 or NUP153 binding to the capsid [57,66]. This comparison also shows that F321 of CPSF6 and F1417 of NUP153 perfectly superpose on the phenyl ring of PF74 (or BI-2) (Figure 4) [65]. As discussed above (Section 2), two most potent capsid inhibitors GS-CA1 and GS-6207 also contain a similar structural moiety (difluorobenzyl) at the topologically equivalent position. This analysis further suggests that chemical features present in host factors can be exploited to develop capsid inhibitors. Indeed, a cyclic peptide (Pep-1) containing chemical features of CPSF6, NUP153, PF74 and BI-2, bind capsid hexamers with nanomolar affinity [65]. Common structural moieties at topologically equivalent positions in CPSF6, NUP154, PF74, BI-2, GS-CA1, GS-6207 and Pep-1 [65] are shown in Table 1.

4. Capsid Inhibitors without PF74 Scaffolds

Other reported capsid inhibitors include benzodiazepine (BD) and benzimidazole (BM) compounds [82,83,84], CAP-1 [43,46], or peptide inhibitors, such as NYAD-1. These compounds do not bind at the PF74 binding site and they inhibit capsid and mature virus by different mechanisms. For example, NYAD-1 disrupts the formation of both immature- and mature-like virus particles [85] and it inhibits viral replication [44,49,52].

5. Conclusions

In conclusion, here we present the current predicted mechanisms of capsid inhibitors containing PF74 scaffold. PF74, although used extensively in experimental settings, has poor metabolic properties suggesting that improved capsid inhibitors can be developed using PF74 as the starting point.

Author Contributions

Conceptualization, C.M. and K.S.; methodology, K.S., F.G., T.P.Q. and C.M., formal analyses, K.S.; writing original draft preparation, K.S. and C.M.; writing—review and editing, C.M., F.G., T.P.Q. and K.S.

Funding

This research was funded by the National Institute of Health R01 Grants GM118012 (subcontract to KS). The study was also supported by the University of Missouri Mizzou Advantage (KS and CM). In addition, K.S. acknowledges support from the Bond Life Sciences Center grant (DU108). CM acknowledges the support from the National Institutes of Health (NIH) Clinical Translational Science Award (CTSA).

Acknowledgments

The authors acknowledge Molecular Interactions Core, University of Missouri for the use of Schrödinger Suite.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Antiretroviral Therapy Cohort Collaboration. Survival of HIV-positive patients starting antiretroviral therapy between 1996 and 2013: A collaborative analysis of cohort studies. Lancet HIV 2017, 4, e349–e356. [Google Scholar] [CrossRef]
  2. Harries, A.D.; Suthar, A.B.; Takarinda, K.C.; Tweya, H.; Kyaw, N.T.; Tayler-Smith, K.; Zachariah, R. Ending the HIV/AIDS epidemic in low- and middle-income countries by 2030: Is it possible? F1000Res 2016, 5, 2328. [Google Scholar] [CrossRef] [PubMed]
  3. Quinn, T.C. HIV epidemiology and the effects of antiviral therapy on long-term consequences. AIDS 2008, 22, S7–S12. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  4. Teeraananchai, S.; Kerr, S.J.; Amin, J.; Ruxrungtham, K.; Law, M.G. Life expectancy of HIV-positive people after starting combination antiretroviral therapy: A meta-analysis. HIV Med. 2017, 18, 256–266. [Google Scholar] [CrossRef] [PubMed]
  5. May, M.T.; Gompels, M.; Delpech, V.; Porter, K.; Orkin, C.; Kegg, S.; Hay, P.; Johnson, M.; Palfreeman, A.; Gilson, R.; et al. Impact on life expectancy of HIV-1 positive individuals of CD4+ cell count and viral load response to antiretroviral therapy. AIDS 2014, 28, 1193–1202. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  6. Sabin, C.A. Do people with HIV infection have a normal life expectancy in the era of combination antiretroviral therapy? BMC Med. 2013, 11, 251. [Google Scholar] [CrossRef]
  7. Pornillos, O.; Ganser-Pornillos, B.K.; Kelly, B.N.; Hua, Y.; Whitby, F.G.; Stout, C.D.; Sundquist, W.I.; Hill, C.P.; Yeager, M. X-ray structures of the hexameric building block of the HIV capsid. Cell 2009, 137, 1282–1292. [Google Scholar] [CrossRef]
  8. Pornillos, O.; Ganser-Pornillos, B.K.; Yeager, M. Atomic-level modelling of the HIV capsid. Nature 2011, 469, 424–427. [Google Scholar] [CrossRef]
  9. Gres, A.T.; Kirby, K.A.; KewalRamani, V.N.; Tanner, J.J.; Pornillos, O.; Sarafianos, S.G. X-ray crystal structures of native HIV-1 capsid protein reveal conformational variability. Science 2015, 349, 99–103. [Google Scholar] [CrossRef] [Green Version]
  10. Arhel, N. Revisiting HIV-1 uncoating. Retrovirology 2010, 7, 96. [Google Scholar] [CrossRef]
  11. Mamede, J.I.; Cianci, G.C.; Anderson, M.R.; Hope, T.J. Early cytoplasmic uncoating is associated with infectivity of HIV-1. Proc. Natl. Acad. Sci. USA 2017, 114, E7169–E7178. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  12. Miller, M.D.; Farnet, C.M.; Bushman, F.D. Human immunodeficiency virus type 1 preintegration complexes: Studies of organization and composition. J. Virol. 1997, 71, 5382–5390. [Google Scholar] [PubMed]
  13. Fassati, A.; Goff, S.P. Characterization of intracellular reverse transcription complexes of human immunodeficiency virus type 1. J. Virol. 2001, 75, 3626–3635. [Google Scholar] [CrossRef] [PubMed]
  14. Hulme, A.E.; Perez, O.; Hope, T.J. Complementary assays reveal a relationship between HIV-1 uncoating and reverse transcription. Proc. Natl. Acad. Sci. USA 2011, 108, 9975–9980. [Google Scholar] [CrossRef] [Green Version]
  15. Hulme, A.E.; Kelley, Z.; Okocha, E.A.; Hope, T.J. Identification of capsid mutations that alter the rate of HIV-1 uncoating in infected cells. J. Virol. 2015, 89, 643–651. [Google Scholar] [CrossRef]
  16. Di Nunzio, F.; Danckaert, A.; Fricke, T.; Perez, P.; Fernandez, J.; Perret, E.; Roux, P.; Shorte, S.; Charneau, P.; Diaz-Griffero, F.; et al. Human nucleoporins promote HIV-1 docking at the nuclear pore, nuclear import and integration. PLoS ONE 2012, 7, e46037. [Google Scholar] [CrossRef]
  17. Schaller, T.; Ocwieja, K.E.; Rasaiyaah, J.; Price, A.J.; Brady, T.L.; Roth, S.L.; Hue, S.; Fletcher, A.J.; Lee, K.; KewalRamani, V.N.; et al. HIV-1 capsid-cyclophilin interactions determine nuclear import pathway, integration targeting and replication efficiency. PLoS Pathog. 2011, 7, e1002439. [Google Scholar] [CrossRef]
  18. Arhel, N.J.; Souquere-Besse, S.; Munier, S.; Souque, P.; Guadagnini, S.; Rutherford, S.; Prevost, M.C.; Allen, T.D.; Charneau, P. HIV-1 DNA flap formation promotes uncoating of the pre-integration complex at the nuclear pore. EMBO J. 2007, 26, 3025–3037. [Google Scholar] [CrossRef]
  19. Campbell, E.M.; Hope, T.J. HIV-1 capsid: The multifaceted key player in HIV-1 infection. Nat. Rev. Microbiol. 2015, 13, 471–483. [Google Scholar] [CrossRef]
  20. Ambrose, Z.; Aiken, C. HIV-1 uncoating: Connection to nuclear entry and regulation by host proteins. Virology 2014, 454–455, 371–379. [Google Scholar] [CrossRef]
  21. Forshey, B.M.; von Schwedler, U.; Sundquist, W.I.; Aiken, C. Formation of a human immunodeficiency virus type 1 core of optimal stability is crucial for viral replication. J. Virol. 2002, 76, 5667–5677. [Google Scholar] [CrossRef] [PubMed]
  22. Rihn, S.J.; Wilson, S.J.; Loman, N.J.; Alim, M.; Bakker, S.E.; Bhella, D.; Gifford, R.J.; Rixon, F.J.; Bieniasz, P.D. Extreme genetic fragility of the HIV-1 capsid. PLoS Pathog. 2013, 9, e1003461. [Google Scholar] [CrossRef] [PubMed]
  23. von Schwedler, U.K.; Stray, K.M.; Garrus, J.E.; Sundquist, W.I. Functional surfaces of the human immunodeficiency virus type 1 capsid protein. J. Virol. 2003, 77, 5439–5450. [Google Scholar] [CrossRef] [PubMed]
  24. Xu, H.; Franks, T.; Gibson, G.; Huber, K.; Rahm, N.; Strambio De Castillia, C.; Luban, J.; Aiken, C.; Watkins, S.; Sluis-Cremer, N.; et al. Evidence for biphasic uncoating during HIV-1 infection from a novel imaging assay. Retrovirology 2013, 10, 70. [Google Scholar] [CrossRef]
  25. Peng, K.; Muranyi, W.; Glass, B.; Laketa, V.; Yant, S.R.; Tsai, L.; Cihlar, T.; Muller, B.; Krausslich, H.G. Quantitative microscopy of functional HIV post-entry complexes reveals association of replication with the viral capsid. Elife 2014, 3, e04114. [Google Scholar] [CrossRef]
  26. Chin, C.R.; Perreira, J.M.; Savidis, G.; Portmann, J.M.; Aker, A.M.; Feeley, E.M.; Smith, M.C.; Brass, A.L. Direct visualization of HIV-1 replication intermediates shows that capsid and CPSF6 modulate HIV-1 intra-nuclear invasion and integration. Cell Rep. 2015, 13, 1717–1731. [Google Scholar] [CrossRef]
  27. Stultz, R.D.; Cenker, J.J.; McDonald, D. Imaging HIV-1 genomic DNA from entry through productive infection. J. Virol. 2017, 91, e00034-17. [Google Scholar] [CrossRef]
  28. Francis, A.C.; Melikyan, G.B. Single HIV-1 imaging reveals progression of infection through CA-dependent steps of docking at the nuclear pore, uncoating, and nuclear transport. Cell Host Microbe 2018, 23, 536–548. [Google Scholar] [CrossRef]
  29. Cosnefroy, O.; Murray, P.J.; Bishop, K.N. HIV-1 capsid uncoating initiates after the first strand transfer of reverse transcription. Retrovirology 2016, 13, 58. [Google Scholar] [CrossRef]
  30. Rankovic, S.; Varadarajan, J.; Ramalho, R.; Aiken, C.; Rousso, I. Reverse transcription mechanically initiates HIV-1 capsid disassembly. J. Virol. 2017, 91, e00289-17. [Google Scholar] [CrossRef]
  31. Lukic, Z.; Dharan, A.; Fricke, T.; Diaz-Griffero, F.; Campbell, E.M. HIV-1 uncoating is facilitated by dynein and kinesin 1. J. Virol. 2014, 88, 13613–13625. [Google Scholar] [CrossRef] [PubMed]
  32. Pawlica, P.; Berthoux, L. Cytoplasmic dynein promotes HIV-1 uncoating. Viruses 2014, 6, 4195–4211. [Google Scholar] [CrossRef] [PubMed]
  33. Sabo, Y.; Walsh, D.; Barry, D.S.; Tinaztepe, S.; de Los Santos, K.; Goff, S.P.; Gundersen, G.G.; Naghavi, M.H. HIV-1 induces the formation of stable microtubules to enhance early infection. Cell Host Microbe 2013, 14, 535–546. [Google Scholar] [CrossRef] [PubMed]
  34. Valle-Casuso, J.C.; Di Nunzio, F.; Yang, Y.; Reszka, N.; Lienlaf, M.; Arhel, N.; Perez, P.; Brass, A.L.; Diaz-Griffero, F. TNPO3 is required for HIV-1 replication after nuclear import but prior to integration and binds the HIV-1 core. J. Virol. 2012, 86, 5931–5936. [Google Scholar] [CrossRef] [PubMed]
  35. Lee, K.; Ambrose, Z.; Martin, T.D.; Oztop, I.; Mulky, A.; Julias, J.G.; Vandegraaff, N.; Baumann, J.G.; Wang, R.; Yuen, W.; et al. Flexible use of nuclear import pathways by HIV-1. Cell Host Microbe 2010, 7, 221–233. [Google Scholar] [CrossRef]
  36. Rasaiyaah, J.; Tan, C.P.; Fletcher, A.J.; Price, A.J.; Blondeau, C.; Hilditch, L.; Jacques, D.A.; Selwood, D.L.; James, L.C.; Noursadeghi, M.; et al. HIV-1 evades innate immune recognition through specific cofactor recruitment. Nature 2013, 503, 402–405. [Google Scholar] [CrossRef]
  37. Fernandez, J.; Machado, A.K.; Lyonnais, S.; Chamontin, C.; Gärtner, K.; Léger, T.; Henriquet, C.; Garcia, C.; Portilho, D.M.; Pugnière, M.; et al. Transportin-1 binds to the HIV-1 capsid via a nuclear localization signal and triggers uncoating. Nat. Microbiol. 2019, 4, 1840–1850. [Google Scholar] [CrossRef]
  38. Craveur, P.; Gres, A.T.; Kirby, K.A.; Liu, D.; Hammond, J.A.; Deng, Y.; Forli, S.; Goodsell, D.S.; Williamson, J.R.; Sarafianos, S.G.; et al. Novel intersubunit interaction critical for HIV-1 core assembly defines a potentially targetable inhibitor binding pocket. mBio 2019, 10. [Google Scholar] [CrossRef]
  39. Li, G.; Verheyen, J.; Rhee, S.Y.; Voet, A.; Vandamme, A.M.; Theys, K. Functional conservation of HIV-1 gag: Implications for rational drug design. Retrovirology 2013, 10, 126. [Google Scholar] [CrossRef]
  40. Prevelige, P.E., Jr. New approaches for antiviral targeting of HIV assembly. J. Mol. Biol. 2011, 410, 634–640. [Google Scholar] [CrossRef]
  41. Bocanegra, R.; Rodriguez-Huete, A.; Fuertes, M.A.; Del Alamo, M.; Mateu, M.G. Molecular recognition in the human immunodeficiency virus capsid and antiviral design. Virus Res. 2012, 169, 388–410. [Google Scholar] [CrossRef] [PubMed]
  42. Ternois, F.; Sticht, J.; Duquerroy, S.; Krausslich, H.G.; Rey, F.A. The HIV-1 capsid protein c-terminal domain in complex with a virus assembly inhibitor. Nat. Struct. Mol. Biol. 2005, 12, 678–682. [Google Scholar] [CrossRef] [PubMed]
  43. Kelly, B.N.; Kyere, S.; Kinde, I.; Tang, C.; Howard, B.R.; Robinson, H.; Sundquist, W.I.; Summers, M.F.; Hill, C.P. Structure of the antiviral assembly inhibitor CAP-1 complex with the HIV-1 CA protein. J. Mol. Biol. 2007, 373, 355–366. [Google Scholar] [CrossRef] [PubMed]
  44. Tang, C.; Loeliger, E.; Kinde, I.; Kyere, S.; Mayo, K.; Barklis, E.; Sun, Y.; Huang, M.; Summers, M.F. Antiviral inhibition of the HIV-1 capsid protein. J. Mol. Biol. 2003, 327, 1013–1020. [Google Scholar] [CrossRef]
  45. Blair, W.S.; Pickford, C.; Irving, S.L.; Brown, D.G.; Anderson, M.; Bazin, R.; Cao, J.; Ciaramella, G.; Isaacson, J.; Jackson, L.; et al. HIV capsid is a tractable target for small molecule therapeutic intervention. PLoS Pathog. 2010, 6, e1001220. [Google Scholar] [CrossRef]
  46. Curreli, F.; Zhang, H.; Zhang, X.; Pyatkin, I.; Victor, Z.; Altieri, A.; Debnath, A.K. Virtual screening based identification of novel small-molecule inhibitors targeted to the HIV-1 capsid. Bioorg. Med. Chem. 2011, 19, 77–90. [Google Scholar] [CrossRef] [Green Version]
  47. Sticht, J.; Humbert, M.; Findlow, S.; Bodem, J.; Muller, B.; Dietrich, U.; Werner, J.; Krausslich, H.G. A peptide inhibitor of HIV-1 assembly in vitro. Nat. Struct. Mol. Biol. 2005, 12, 671–677. [Google Scholar] [CrossRef]
  48. Xu, J.P.; Francis, A.C.; Meuser, M.E.; Mankowski, M.; Ptak, R.G.; Rashad, A.A.; Melikyan, G.B.; Cocklin, S. Exploring modifications of an HIV-1 capsid inhibitor: Design, synthesis, and mechanism of action. J. Drug Des. Res. 2018, 5, 1070. [Google Scholar]
  49. Kortagere, S.; Madani, N.; Mankowski, M.K.; Schon, A.; Zentner, I.; Swaminathan, G.; Princiotto, A.; Anthony, K.; Oza, A.; Sierra, L.J.; et al. Inhibiting early-stage events in HIV-1 replication by small-molecule targeting of the HIV-1 capsid. J. Virol. 2012, 86, 8472–8481. [Google Scholar] [CrossRef]
  50. Kortagere, S.; Xu, J.P.; Mankowski, M.K.; Ptak, R.G.; Cocklin, S. Structure-activity relationships of a novel capsid targeted inhibitor of HIV-1 replication. J. Chem. Inf. Model. 2014, 54, 3080–3090. [Google Scholar] [CrossRef]
  51. Xu, J.P.; Branson, J.D.; Lawrence, R.; Cocklin, S. Identification of a small molecule HIV-1 inhibitor that targets the capsid hexamer. Bioorg. Med. Chem. Lett. 2016, 26, 824–828. [Google Scholar] [CrossRef] [PubMed]
  52. Lamorte, L.; Titolo, S.; Lemke, C.T.; Goudreau, N.; Mercier, J.F.; Wardrop, E.; Shah, V.B.; von Schwedler, U.K.; Langelier, C.; Banik, S.S.; et al. Discovery of novel small-molecule HIV-1 replication inhibitors that stabilize capsid complexes. Antimicrob. Agents Chemother. 2013, 57, 4622–4631. [Google Scholar] [CrossRef] [PubMed]
  53. Siddiqui, M.A.; Saito, A.; Halambage, U.D.; Ferhadian, D.; Fischer, D.K.; Francis, A.C.; Melikyan, G.B.; Ambrose, Z.; Aiken, C.; Yamashita, M. A novel phenotype links HIV-1 capsid stability to cgas-mediated DNA sensing. J. Virol. 2019. [Google Scholar] [CrossRef] [PubMed]
  54. Balasubramaniam, M.; Zhou, J.; Addai, A.; Martinez, P.; Pandhare, J.; Aiken, C.; Dash, C. PF74 inhibits HIV-1 integration by altering the composition of the preintegration complex. J. Virol. 2019, 93, e01741-18. [Google Scholar] [CrossRef] [PubMed]
  55. Zhou, J.; Price, A.J.; Halambage, U.D.; James, L.C.; Aiken, C. HIV-1 resistance to the capsid-targeting inhibitor PF74 results in altered dependence on host factors required for virus nuclear entry. J. Virol. 2015, 89, 9068–9079. [Google Scholar] [CrossRef] [PubMed]
  56. Shi, J.; Zhou, J.; Shah, V.B.; Aiken, C.; Whitby, K. Small-molecule inhibition of human immunodeficiency virus type 1 infection by virus capsid destabilization. J. Virol. 2011, 85, 542–549. [Google Scholar] [CrossRef]
  57. Price, A.J.; Jacques, D.A.; McEwan, W.A.; Fletcher, A.J.; Essig, S.; Chin, J.W.; Halambage, U.D.; Aiken, C.; James, L.C. Host cofactors and pharmacologic ligands share an essential interface in HIV-1 capsid that is lost upon disassembly. PLoS Pathog. 2014, 10, e1004459. [Google Scholar] [CrossRef]
  58. Bhattacharya, A.; Alam, S.L.; Fricke, T.; Zadrozny, K.; Sedzicki, J.; Taylor, A.B.; Demeler, B.; Pornillos, O.; Ganser-Pornillos, B.K.; Diaz-Griffero, F.; et al. Structural basis of HIV-1 capsid recognition by PF74 and CPSF6. Proc. Natl. Acad. Sci. USA 2014, 111, 18625–18630. [Google Scholar] [CrossRef] [Green Version]
  59. Wu, G.; Zalloum, W.A.; Meuser, M.E.; Jing, L.; Kang, D.; Chen, C.H.; Tian, Y.; Zhang, F.; Cocklin, S.; Lee, K.H.; et al. Discovery of phenylalanine derivatives as potent HIV-1 capsid inhibitors from click chemistry-based compound library. Eur. J. Med. Chem. 2018, 158, 478–492. [Google Scholar] [CrossRef]
  60. Tse, W.C.; Link, J.O.; Mulato, A.; Niedziela-Majka, A.; Rowe, W.; Somoza, J.R.; Villasenor, A.G.; Yant, S.R.; Zhang, J.R.; Zheng, J. Discovery of novel potent HIV capsid inhibitors with long-acting potential. In Proceedings of the Conference on Retroviruses and Opportunistic Infections, Abstract No. 38, Seattle, WA, USA, 13–16 February 2017. [Google Scholar]
  61. Zheng, J.; Yant, S.R.; Ahmadyar, S.; Chan, T.Y.; Chiu, A.; Cihlar, T.; Link, J.O.; Lu, B.; Mwangi, J.; Rowe, W.; et al. 539. Gs-ca2: A novel, potent, and selective first-in-class inhibitor of HIV-1 capsid function displays nonclinical pharmacokinetics supporting long-acting potential in humans. Open Forum Infect. Dis. 2018, 5, S199–S200. [Google Scholar] [CrossRef]
  62. Carnes, S.K.; Sheehan, J.H.; Aiken, C. Inhibitors of the HIV-1 capsid, a target of opportunity. Curr. Opin. HIV AIDS 2018, 13, 359–365. [Google Scholar] [CrossRef] [PubMed]
  63. Jarvis, L.M. Conquering HIV’s capsid. Chem. Eng. News 2017, 95, 23–25. [Google Scholar]
  64. Berman, H.M.; Westbrook, J.; Feng, Z.; Gilliland, G.; Bhat, T.N.; Weissig, H.; Shindyalov, I.N.; Bourne, P.E. The protein data bank. Nucleic Acids Res. 2000, 28, 235–242. [Google Scholar] [CrossRef] [PubMed]
  65. Singh, K.; Gallazzi, F.; Hill, K.J.; Burke, D.H.; Lange, M.J.; Quinn, T.P.; Neogi, U.; Sonnerborg, A. Gs-CA compounds: First-in-class HIV-1 capsid inhibitors covering multiple grounds. Front. Microbiol. 2019, 10, 1227. [Google Scholar] [CrossRef] [PubMed]
  66. Price, A.J.; Fletcher, A.J.; Schaller, T.; Elliott, T.; Lee, K.; KewalRamani, V.N.; Chin, J.W.; Towers, G.J.; James, L.C. CPSF6 defines a conserved capsid interface that modulates HIV-1 replication. PLoS Pathog. 2012, 8, e1002896. [Google Scholar] [CrossRef] [PubMed]
  67. Perrier, M.; Bertine, M.; Le Hingrat, Q.; Joly, V.; Visseaux, B.; Collin, G.; Landman, R.; Yazdanpanah, Y.; Descamps, D.; Charpentier, C. Prevalence of gag mutations associated with in vitro resistance to capsid inhibitor gs-ca1 in HIV-1 antiretroviral-naive patients. J. Antimicrob. Chemother. 2017, 72, 2954–2955. [Google Scholar] [CrossRef]
  68. Yant, S.R.; Mulato, A.; Hansen, D.; Tse, W.C.; Niedziela-Majka, A.; Zhang, J.R.; Stepan, G.J.; Jin, D.; Wong, M.H.; Perreira, J.M.; et al. A highly potent long-acting small-molecule HIV-1 capsid inhibitor with efficacy in a humanized mouse model. Nat. Med. 2019, 25, 1377–1384. [Google Scholar] [CrossRef]
  69. Jacques, D.A.; McEwan, W.A.; Hilditch, L.; Price, A.J.; Towers, G.J.; James, L.C. HIV-1 uses dynamic capsid pores to import nucleotides and fuel encapsidated DNA synthesis. Nature 2016, 536, 349–353. [Google Scholar] [CrossRef]
  70. Halgren, T.A. Identifying and characterizing binding sites and assessing druggability. J. Chem. Inf. Model. 2009, 49, 377–389. [Google Scholar] [CrossRef]
  71. Egan, W.J.; Merz, K.M., Jr.; Baldwin, J.J. Prediction of drug absorption using multivariate statistics. J. Med. Chem. 2000, 43, 3867–3877. [Google Scholar] [CrossRef]
  72. Muegge, I.; Heald, S.L.; Brittelli, D. Simple selection criteria for drug-like chemical matter. J. Med. Chem. 2001, 44, 1841–1846. [Google Scholar] [CrossRef] [PubMed]
  73. Sowd, G.A.; Serrao, E.; Wang, H.; Wang, W.; Fadel, H.J.; Poeschla, E.M.; Engelman, A.N. A critical role for alternative polyadenylation factor CPSF6 in targeting HIV-1 integration to transcriptionally active chromatin. Proc. Natl. Acad. Sci. USA 2016, 113, E1054–E1063. [Google Scholar] [CrossRef] [PubMed]
  74. Buffone, C.; Martinez-Lopez, A.; Fricke, T.; Opp, S.; Severgnini, M.; Cifola, I.; Petiti, L.; Frabetti, S.; Skorupka, K.; Zadrozny, K.K.; et al. Nup153 unlocks the nuclear pore complex for HIV-1 nuclear translocation in nondividing cells. J. Virol. 2018, 92, e00648-18. [Google Scholar] [CrossRef] [PubMed]
  75. Bejarano, D.A.; Peng, K.; Laketa, V.; Borner, K.; Jost, K.L.; Lucic, B.; Glass, B.; Lusic, M.; Muller, B.; Krausslich, H.G. HIV-1 nuclear import in macrophages is regulated by CPSF6-capsid interactions at the nuclear pore complex. Elife 2019, 8, e41800. [Google Scholar] [CrossRef]
  76. Di Nunzio, F.; Fricke, T.; Miccio, A.; Valle-Casuso, J.C.; Perez, P.; Souque, P.; Rizzi, E.; Severgnini, M.; Mavilio, F.; Charneau, P.; et al. Nup153 and nup98 bind the HIV-1 core and contribute to the early steps of HIV-1 replication. Virology 2013, 440, 8–18. [Google Scholar] [CrossRef]
  77. Matreyek, K.A.; Engelman, A. The requirement for nucleoporin NUP153 during human immunodeficiency virus type 1 infection is determined by the viral capsid. J. Virol. 2011, 85, 7818–7827. [Google Scholar] [CrossRef]
  78. Matreyek, K.A.; Yucel, S.S.; Li, X.; Engelman, A. Nucleoporin NUP153 phenylalanine-glycine motifs engage a common binding pocket within the HIV-1 capsid protein to mediate lentiviral infectivity. PLoS Pathog. 2013, 9, e1003693. [Google Scholar] [CrossRef]
  79. Achuthan, V.; Perreira, J.M.; Sowd, G.A.; Puray-Chavez, M.; McDougall, W.M.; Paulucci-Holthauzen, A.; Wu, X.; Fadel, H.J.; Poeschla, E.M.; Multani, A.S.; et al. Capsid-CPSF6 interaction licenses nuclear HIV-1 trafficking to sites of viral DNA integration. Cell Host Microbe 2018, 24, 392–404. [Google Scholar] [CrossRef]
  80. Rasheedi, S.; Shun, M.C.; Serrao, E.; Sowd, G.A.; Qian, J.; Hao, C.; Dasgupta, T.; Engelman, A.N.; Skowronski, J. The cleavage and polyadenylation specificity factor 6 (CPSF6) subunit of the capsid-recruited pre-messenger RNA cleavage factor i (cfim) complex mediates HIV-1 integration into genes. J. Biol. Chem. 2016, 291, 11809–11819. [Google Scholar] [CrossRef]
  81. Yamashita, M.; Engelman, A.N. Capsid-dependent host factors in HIV-1 infection. Trends Microbiol 2017, 25, 741–755. [Google Scholar] [CrossRef]
  82. Fader, L.D.; Bethell, R.; Bonneau, P.; Bos, M.; Bousquet, Y.; Cordingley, M.G.; Coulombe, R.; Deroy, P.; Faucher, A.M.; Gagnon, A.; et al. Discovery of a 1,5-dihydrobenzo[b][1,4]diazepine-2,4-dione series of inhibitors of HIV-1 capsid assembly. Bioorg. Med. Chem. Lett. 2011, 21, 398–404. [Google Scholar] [CrossRef] [PubMed]
  83. Lemke, C.T.; Titolo, S.; von Schwedler, U.; Goudreau, N.; Mercier, J.F.; Wardrop, E.; Faucher, A.M.; Coulombe, R.; Banik, S.S.; Fader, L.; et al. Distinct effects of two HIV-1 capsid assembly inhibitor families that bind the same site within the n-terminal domain of the viral CA protein. J. Virol. 2012, 86, 6643–6655. [Google Scholar] [CrossRef] [PubMed]
  84. Tremblay, M.; Bonneau, P.; Bousquet, Y.; DeRoy, P.; Duan, J.; Duplessis, M.; Gagnon, A.; Garneau, M.; Goudreau, N.; Guse, I.; et al. Inhibition of HIV-1 capsid assembly: Optimization of the antiviral potency by site selective modifications at N1, C2 and C16 of a 5-(5-furan-2-yl-pyrazol-1-yl)-1h-benzimidazole scaffold. Bioorg. Med. Chem. Lett. 2012, 22, 7512–7517. [Google Scholar] [CrossRef] [PubMed]
  85. Zhang, H.; Curreli, F.; Waheed, A.A.; Mercredi, P.Y.; Mehta, M.; Bhargava, P.; Scacalossi, D.; Tong, X.; Lee, S.; Cooper, A.; et al. Dual-acting stapled peptides target both HIV-1 entry and assembly. Retrovirology 2013, 10, 136. [Google Scholar] [CrossRef] [PubMed]
Diseases 07 00056 g001 550
Figure 1. Structure of HIV-1 capsid. (a) Structure of capsid (CA) monomer. This figure was generated from the X-ray crystal structure of native HIV-1 capsid protein bound to PF74 [9] (PDB entry 4XFZ). NTD: N-terminal domain. CTD: C-terminal domain. Panels (b,c) show hexamer and pentamers formed from the same CA monomer. (d) Approximately 250 hexamers and 12 pentamers form a conical shaped capsid that houses necessary and sufficient components to initiate reverse transcription immediately after infection. Panel d is reproduced from PDB101 with permission.
Figure 1. Structure of HIV-1 capsid. (a) Structure of capsid (CA) monomer. This figure was generated from the X-ray crystal structure of native HIV-1 capsid protein bound to PF74 [9] (PDB entry 4XFZ). NTD: N-terminal domain. CTD: C-terminal domain. Panels (b,c) show hexamer and pentamers formed from the same CA monomer. (d) Approximately 250 hexamers and 12 pentamers form a conical shaped capsid that houses necessary and sufficient components to initiate reverse transcription immediately after infection. Panel d is reproduced from PDB101 with permission.
Diseases 07 00056 g001
Diseases 07 00056 g002 550
Figure 2. Structures of PF74 and GS-CA compounds. (a) PF74 can be divided into three components: polyphenyl core (red), linker (blue) and substituent (violet). Numbers 1, 2 and 3 represent three ring structures in PF74. Panels (b) and (c) show the chemical structure of GS-CA1 and GS-6207 compounds, respectively. Chemical moieties colored red, blue and violet correspond to those in PF74 (panel a). (d) Superposition of PF74 and GS-CA1. Dotted circles show the superposition of three ring structures present in PF74, GS-CA1 and GS-6207.
Figure 2. Structures of PF74 and GS-CA compounds. (a) PF74 can be divided into three components: polyphenyl core (red), linker (blue) and substituent (violet). Numbers 1, 2 and 3 represent three ring structures in PF74. Panels (b) and (c) show the chemical structure of GS-CA1 and GS-6207 compounds, respectively. Chemical moieties colored red, blue and violet correspond to those in PF74 (panel a). (d) Superposition of PF74 and GS-CA1. Dotted circles show the superposition of three ring structures present in PF74, GS-CA1 and GS-6207.
Diseases 07 00056 g002
Diseases 07 00056 g003 550
Figure 3. Hydrophobic pockets between two capsid monomers. This figure shows the hydrophobic pockets (orange wire-mesh) present between two capsid monomers of a hexamer. The amino acid residues that contribute in formation of hydrophobic pockets are displayed in ball-and-stick representation. The presence of hydrophobic pockets 4, 5 and 6 suggests that the conformation of methanesulfonyl moieties of GS-CA1 and GS-6207 can assume a conformation that is 180° rotated from previously predicted [65]. Note that hydrophobic pockets 1, 2 and 3 are at a topologically equivalent position to three ring structures of PF74, GS-CA1 or GS-6207.
Figure 3. Hydrophobic pockets between two capsid monomers. This figure shows the hydrophobic pockets (orange wire-mesh) present between two capsid monomers of a hexamer. The amino acid residues that contribute in formation of hydrophobic pockets are displayed in ball-and-stick representation. The presence of hydrophobic pockets 4, 5 and 6 suggests that the conformation of methanesulfonyl moieties of GS-CA1 and GS-6207 can assume a conformation that is 180° rotated from previously predicted [65]. Note that hydrophobic pockets 1, 2 and 3 are at a topologically equivalent position to three ring structures of PF74, GS-CA1 or GS-6207.
Diseases 07 00056 g003
Diseases 07 00056 g004 550
Figure 4. Superposition of CPSF6, NUP153 and PF74. The dotted circle highlights the equivalent position of phenylalanine residues in CPSF6 and NUP153 and one of the two phenyl rings of PF74. The equivalent ring structure in GS-CA1 and GS-6207 is difluorobenzene, which is not shown in this figure. The structures of capsid inhibitors shown here have either been solved or in complex with capsid.
Figure 4. Superposition of CPSF6, NUP153 and PF74. The dotted circle highlights the equivalent position of phenylalanine residues in CPSF6 and NUP153 and one of the two phenyl rings of PF74. The equivalent ring structure in GS-CA1 and GS-6207 is difluorobenzene, which is not shown in this figure. The structures of capsid inhibitors shown here have either been solved or in complex with capsid.
Diseases 07 00056 g004
Table
Table 1. Structural similarity among PF74, PF74-based compounds and host factors.
Table 1. Structural similarity among PF74, PF74-based compounds and host factors.
PF74BI-2CPSF6NUP153GS-CA1GS-6207Pep-1
phenylphenylF321F1417difluorobenzyldifluorobenzylphenylalanine
phenylphenol--IndazoleIndazoleproline
indole-G318-Q3191-cyclopenta-pyrazolecyclopenta-pyrazolevaline
-- F1415methanesulfonylmethanesulfonylphenylalanine
1 A part of G318-Q319 dipeptide of CPSF6 is topologically close to the indole ring of PF74.

Share and Cite

MDPI and ACS Style

McArthur, C.; Gallazzi, F.; Quinn, T.P.; Singh, K. HIV Capsid Inhibitors Beyond PF74. Diseases 2019, 7, 56. https://doi.org/10.3390/diseases7040056

AMA Style

McArthur C, Gallazzi F, Quinn TP, Singh K. HIV Capsid Inhibitors Beyond PF74. Diseases. 2019; 7(4):56. https://doi.org/10.3390/diseases7040056

Chicago/Turabian Style

McArthur, Carole, Fabio Gallazzi, Thomas P. Quinn, and Kamal Singh. 2019. "HIV Capsid Inhibitors Beyond PF74" Diseases 7, no. 4: 56. https://doi.org/10.3390/diseases7040056

APA Style

McArthur, C., Gallazzi, F., Quinn, T. P., & Singh, K. (2019). HIV Capsid Inhibitors Beyond PF74. Diseases, 7(4), 56. https://doi.org/10.3390/diseases7040056

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop